Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Top Cited Papers
- 29 October 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 9 (11), 883-897
- https://doi.org/10.1038/nrd3248
Abstract
The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system. Elucidation of the effects of fingolimod--mediated by the modulation of sphingosine 1-phosphate (S1P) receptors--has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes. An improved understanding of the biology of S1P receptors has also been gained. This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in September 2010 as a first-line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease-modifying therapy to be approved for multiple sclerosis in the United States.Keywords
This publication has 153 references indexed in Scilit:
- Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kineticsThe Journal of Experimental Medicine, 2010
- Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune EncephalomyelitisImmunity, 2010
- Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterningThe Journal of Experimental Medicine, 2009
- Sphingosine-1-phosphate and modulation of vascular toneCardiovascular Research, 2009
- Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cellsNature Immunology, 2008
- The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjectsBritish Journal of Clinical Pharmacology, 2008
- Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff diseaseHuman Molecular Genetics, 2008
- S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell EgressImmunity, 2008
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- Serine Palmitoyltransferase Is the Primary Target of a Sphingosine-like Immunosuppressant, ISP-1/MyriocinBiochemical and Biophysical Research Communications, 1995